Meta-analysis of 16 real-world studies in children with SLE: add-on belimumab vs standard immunotherapy gave greater SLEDAI reduction (MD 2.86), fewer adverse events (RR 0.37) and higher lupus nephritis remission at 6 months, and lower 12-month flare risk (RR 0.44).
Meta-analysisn = 16 studies
Le et al. Long-term efficacy and safety of belimumab in children with systemic lupus erythematosus: a meta-analysis of real-world data